← Back to Search
Clinical Development Of The Anti-CTLA-4 Antibody Tremelimumab.
Published 2010 · Medicine
Download PDFAnalyze on Scholarcy
Tremelimumab (formerly CP-675,206) is a fully human IgG2 monoclonal antibody tested in patients with cancer, of whom the majority have had metastatic melanoma. Clinical trials using tremelimumab demonstrate that this antibody can induce durable tumor regressions (up to 8 years at this time) in 7% to 10% of patients with metastatic melanoma. These tumor responses are mediated by the intratumoral infiltration of cytotoxic T lymphocytes (CTLs) as demonstrated in patient-derived tumor biopsies. Grade 3 or 4 toxicities in the range of 20% to 25% are mainly inflammatory or autoimmune in nature, which are on-target effects after inhibiting CTLA-4-mediated self-tolerance. The lack of survival advantage in the early analysis of a phase III clinical trial comparing tremelimumab with standard chemotherapy for metastatic melanoma highlights the importance of gaining a better understanding of how this antibody modulates the human immune system and how to better select patients for this mode of therapy.
This paper references
Immune response in malignant ascites from a melanoma patient treated with anti-CTLA-4 mAb
H. Harlin (2004)
Checkpoint blockade in cancer immunotherapy.
A. Korman (2006)
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
D. Munn (2004)
Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206).
R. Millham (2006)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Ido expression by dendritic cells: tolerance and tryptophan catabolism
A. Mellor (2004)
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
C. Ménard (2008)
Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy
A. Ribas (2004)
CTLA-4–Ig regulates tryptophan catabolism in vivo
U. Grohmann (2002)
Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
A. Ribas (2009)
Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
A. Ribas (2010)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma
A. Ribas (2005)
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
A. Ribas (2007)
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
S. Agarwala (2010)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
M. Brüggemann (1987)
Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma.
M. A. Marshall (2010)
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
L. Chen (2004)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas (2008)
Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.
D. C. Hanson (2004)
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
B. Comin-Anduix (2008)
Phospho‐proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single‐cell level
O. Perez (2006)
Metabolic properties of IgG subclasses in man.
A. Morell (1970)
Modulation of tryptophan catabolism by regulatory T cells
F. Fallarino (2003)
Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma
J. Reuben (2006)
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
C. A. Chambers (2001)
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
A. Ribas (2009)
Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays
B. Comin-Anduix (2006)
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.
A. Hryniewicz (2006)
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
A. Ribas (2009)
Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease.
S. Paust (2004)
PET Imaging of Cancer Immunotherapy
P. Tumeh (2008)
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
L. Camacho (2009)
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
B. Comin-Anduix (2010)
This paper is referenced by
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
R. Huang (2011)
Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
J. Pérez-Gracia (2014)
Novel antibodies targeting immune regulatory checkpoints for cancer therapy
C. Lee (2013)
Investigating the role of PD-L1 pathway in human ovarian cancer
Jay Chatterjee (2014)
Toll-like receptor agonists for cancer therapy
E. Vacchelli (2013)
B7 family checkpoint regulators in immune regulation and disease.
S. Ceeraz (2013)
Esophageal malignant melanoma: analysis of 134 cases collected by the Japan Esophageal Society
H. Makuuchi (2015)
Progress in Clinical Use of CC Chemokine Receptor 4 Antibody for Regulatory T Cell Suppression
S. Suzuki (2015)
The characteristic expression of B7-associated proteins in Langerhans cell sarcoma.
H. Li (2012)
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
C. Robert (2013)
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
M. R. Girotti (2014)
Frequency of non-cancer-related pain in patients with cancer.
L. Barbera (2013)
Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints
K. S. Yogesh (2012)
Modulation of T regulatory activity for cancer therapy
C. Ralph (2011)
Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma
S. Tomei (2014)
Use of ipilimumab in the treatment of melanoma
U. Acharya (2013)
B Cell Epitope-Based Vaccination Therapy
Y. Kametani (2015)
Immunological biomarkers of outcome in thoracic cancers
T. Meniawy (2016)
Advances in cutaneous melanoma
E. Espinosa (2012)
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
G. Clifton (2015)
Cancer immunotherapy comes of age
I. Mellman (2011)
Cancer Immunotherapy Comes of Age
M. Karsy (2013)
Immune Checkpoint Inhibitors in Sarcoma
S. D'Angelo (2019)
Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer
Shao-bo Yang (2011)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Z. Eroglu (2015)
Cancer immunotherapy comes of age.
S. Topalian (2011)
Foundation review : The future of antibodies as cancer drugs
J. Reichert (2012)
Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
S. Hwang (2018)
CD28 co-stimulation in T-cell homeostasis: a recent perspective
N. Beyersdorf (2015)
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
M. Porcu (2019)
Retaining antibodies in tumors with a self-assembling injectable system.
Y. Wen (2013)See more